Prof. Lars Dyrskjøt at the European Association of Urology (EAU) Congress 2025
- Mar 27
- 1 min read
The European Association of Urology (EAU) Congress 2025 was held from 21–24 March in Madrid, Spain, bringing together international experts to explore cutting-edge developments in urological research and care. As part of the plenary session on Biomarkers to Guide Peri-operative Management in Onco-Urology", Prof. Lars Dyrskjøt from Aarhus University - a partner in the MULTIR project—took part in the expert panel discussion, sharing his perspectives on how biomarkers can help refine treatment strategies for urological cancers.
Prof. Dyrskjøt’s contribution highlighted the potential of biomarker-driven stratification tools to enhance clinical decision-making, particularly in personalizing therapy for bladder cancer. His insights reflect the aims of the MULTIR project, which seeks to integrate biomarker data into predictive models to support individualized treatment planning.
The session also explored practical considerations around the clinical use of biomarkers—such as identifying patients who would benefit most from intensified treatment regimens, and leveraging molecular profiling to guide the selection of chemotherapy, immunotherapy, or surgical approaches. These discussions resonate strongly with MULTIR’s commitment to advancing risk stratification through multi-modal data analysis, ultimately supporting more targeted and effective patient care.
Session Highlights: Read the summary
